Literature DB >> 34185896

Status Toward the Implementation of Precision Dosing in Children.

Jeffrey S Barrett1, Ryan F Barrett2, Alexander A Vinks3,4.   

Abstract

Precision dosing is progressing beyond the conceptual and proof-of-concept stages toward implementation. As the availability of dosing algorithms, tools, and platforms increases, so do the investment in technology services and actual implementation of clinical services offering these solutions to patients. Nowhere is this needed more than in pediatric populations, which are still reliant on adult drug development and bridging strategies to support dosing, often in the absence of actual dose-finding studies in the target pediatric population. Still, there is more work to be done to ensure that proper governance of these services is maintained, and that sustainability of these early implementations is guided by new science as it evolves and meaningful outcome data to confirm that such services deliver on both clinical and economic return on investment. In addition, the field should ensure that all approaches beyond a therapeutic drug monitoring-driven, pharmacokinetic-centric approach should be considered as the tools and services evolve, especially when pediatric-specific pharmacokinetic/pharmacodyamic and pharmacogenetic data are available and shown to be useful to guide dosing. This review evaluates current pediatric precision dosing efforts, highlighting their utility, longevity, and sustainability and assesses the current process for implementing such approaches examining current barriers that stand in the way of broader implementation and the stakeholders that must engage to ensure its ultimate success.
© 2021, The American College of Clinical Pharmacology.

Entities:  

Keywords:  MIPD; pediatrics; precision dosing

Mesh:

Substances:

Year:  2021        PMID: 34185896     DOI: 10.1002/jcph.1830

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  2 in total

1.  A General Biphasic Bodyweight Model for Scaling Basal Metabolic Rate, Glomerular Filtration Rate, and Drug Clearance from Birth to Adulthood.

Authors:  Teh-Min Hu
Journal:  AAPS J       Date:  2022-05-10       Impact factor: 3.603

2.  Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT.

Authors:  Kana Mizuno; Christopher E Dandoy; Ashley Teusink-Cross; Stella M Davies; Alexander A Vinks; Sonata Jodele
Journal:  Blood Adv       Date:  2022-03-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.